Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8227861 | 0.86 | PDK1 (0.38) | PDK1KDM1ADRD1GLRA1 | |
| SCHEMBL20921432 | 0.85 | PIK3CD (0.42) | PDK1KDM1ADRD1GLRA1CNR1 | |
| SCHEMBL17828068 | 0.85 | PIK3CD (0.42) | PDK1KDM1ADRD1GLRA1CNR1 | |
| SCHEMBL18556758 | 0.85 | PIK3CD (0.42) | PDK1KDM1ADRD1GLRA1CNR1 | |
| SCHEMBL9801239 | 0.81 | PDK1 (0.43) | PDK1KDM1ADRD1GLRA1KDM4E | |
| SCHEMBL26817757 | 0.79 | PDK1 (0.44) | PDK1KDM1ADRD1GLRA1CNR2 | |
| SCHEMBL9801377 | 0.79 | HRH3 (0.32) | PDK1 | |
| Hydrochloric Acid SCHEMBL2172505 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL20807806 | 0.76 | — | — | |
| SCHEMBL4317037 | 0.76 | EBP (0.44) | PDK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017017630-A1 | NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-02-02 | — | — | WO | disclosed |
| EP-2994470-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014182829-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | WO | disclosed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2341886-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NovaBay Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2212332-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010054269-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
| EP-2021316-A1 | INHIBITORS OF POLO-LIKE KINASES | Abbott Laboratories (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007140233-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PCNA | PDK1 993/4885KDM1A 2885/4885DRD1 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.